AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Fiercepharma

Published November 2, 2026 · Updated November 3, 2026

Compass points to unmet need in depression as landmark psychedelic nears market

Read the full story at Fiercepharma

Asia · Cell & Gene Therapy · Drug Delivery · Executives · Manufacturing ... Related. Scaling psychedelics comes with uncertainty 'baked into the sauce'.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics asia